UCB, a Brussels, Belgium-based bio/pharmaceutical company, has selected Rowen, Gwinnett County, Georgia, as the location for its new US biologics manufacturing facility. UCB announced plans to invest in the new facility in June 2025. 

Spanning approximately 460,000 square feet, the campus will sit on 79 acres and will become part of UCB’s biologics manufacturing network. Once operational, the facility is expected to produce complex biologics 24/7 primarily for the US market. Since 2017, the company has received 16 US Food and Drug Administration approvals or indication expansions, which include nine of which came over the past three years (as reported on March 24, 2026). 

The new manufacturing facility will serve as an anchor tenant in Rowen, a 2,000-acre planned community in metro Atlanta designed to foster collaboration, knowledge sharing, and innovation and developed as a strategic partnership between the Rowen Foundation, a non-profit instituion, and Gwinnett County. The company’s US headquarters is nearby in Symra, Georgia.  

The new facility is expected to create around 330 permanent direct jobs in biologics manufacturing and more than 1,000 jobs during construction. The company has not disclosed the level of its investment in the new facility but estimates that the new facility will have a total economic impact of $5 billion.   

Source: UCB and Governor’s Office in Georgia